However, although the bulk tumor levels may have been reduced, this phenomenon alone does not warrant it to be sufficient evidence in categorizing mithramycin A as specific SETDB1 target or in suggesting it to abrogate CSC development. Here, SETDB1 is linked to neoplasm.